相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。High PD-1 expression level is associated with an unfavorable prognosis in patients with cervical adenocarcinoma
Masako Ishikawa et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2020)
CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy
Hiroshi Kagamu et al.
CANCER IMMUNOLOGY RESEARCH (2020)
Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer
David Y. Oh et al.
CELL (2020)
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer
Patrick A. Ott et al.
CELL (2020)
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
Reinhard Dummer et al.
NATURE MEDICINE (2020)
Interleukin-2 signals converge in a lymphoid-dendritic cell pathway that promotes anticancer immunity
Miro E. Raeber et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors
Patrick A. Ott et al.
CANCER DISCOVERY (2019)
Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy
Melvyn T. Chow et al.
IMMUNITY (2019)
Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy
Mauro Di Pilato et al.
NATURE (2019)
The IRE1 endoplasmic reticulum stress sensor activates natural killer cell immunity in part by regulating c-Myc
Han Dong et al.
NATURE IMMUNOLOGY (2019)
Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination
Linda Hammerich et al.
NATURE MEDICINE (2019)
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
Leonie Voorwerk et al.
NATURE MEDICINE (2019)
Clonal replacement of tumor-specific T cells following PD-1 blockade
Kathryn E. Yost et al.
NATURE MEDICINE (2019)
Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy
Shiping Jiao et al.
CELL (2019)
MHC-II neoantigens shape tumour immunity and response to immunotherapy
Elise Alspach et al.
NATURE (2019)
PD1Hi CD8+ T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma
Jiaqiang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
The IL-15-AKT-XBP1s signaling pathway contributes to effector functions and survival in human NK cells
Yufeng Wang et al.
NATURE IMMUNOLOGY (2019)
A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity
Hayley S. Ma et al.
CANCER IMMUNOLOGY RESEARCH (2019)
IRE1α Activation in Bone Marrow-Derived Dendritic Cells Modulates Innate Recognition of Melanoma Cells and Favors CD8+ T Cell Priming
Bernardita Medel et al.
FRONTIERS IN IMMUNOLOGY (2019)
Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
Jean-Charles Cancel et al.
FRONTIERS IN IMMUNOLOGY (2019)
Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity
Brendan L. Horton et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Mechanisms of resistance to immune checkpoint inhibitors
Russell W. Jenkins et al.
BRITISH JOURNAL OF CANCER (2018)
Non-conventional Inhibitory CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity
Roberta Zappasodi et al.
CANCER CELL (2018)
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
Roberta Zappasodi et al.
CANCER CELL (2018)
NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control
Jan P. Boettcher et al.
CELL (2018)
Antigen presentation unfolded: identifying convergence points between the UPR and antigen presentation pathways
Fabiola Osorio et al.
CURRENT OPINION IN IMMUNOLOGY (2018)
Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy
Jinyang Li et al.
IMMUNITY (2018)
Inhibitors of the PD-1 Pathway in Tumor Therapy
Martin W. LaFleur et al.
JOURNAL OF IMMUNOLOGY (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Deconvolution of plasma-derived exosomes for tracking and prediction of immunotherapy across multiple tissues
Alvin Shi et al.
CANCER RESEARCH (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus-Derived Vectors Fosters Dendritic Cell-Mediated T-cell Cross-Priming
Alfonso R. Sanchez-Paulete et al.
CANCER RESEARCH (2018)
IRE1 alpha-XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity
Minkyung Song et al.
NATURE (2018)
Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2
Zuqiang Liu et al.
NATURE COMMUNICATIONS (2018)
Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into CheckpointResponsive Tumors by Reprogramming Tumor-Infiltrating MDSCs
Brian J. Christmas et al.
CANCER IMMUNOLOGY RESEARCH (2018)
CD4+ T cell help in cancer immunology and immunotherapy
Jannie Borst et al.
NATURE REVIEWS IMMUNOLOGY (2018)
CD8+ T Cells Orchestrate pDC-XCR1+ Dendritic Cell Spatial and Functional Cooperativity to Optimize Priming
Anna Brewitz et al.
IMMUNITY (2017)
Regulated IRE1-dependent mRNA decay sets the threshold for dendritic cell survival
Simon J. Tavernier et al.
NATURE CELL BIOLOGY (2017)
Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes
Jingjing Zhu et al.
NATURE COMMUNICATIONS (2017)
The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy
Daniel Zingg et al.
CELL REPORTS (2017)
PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer
Benjamin A. Kansy et al.
CANCER RESEARCH (2017)
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40
David J. Messenheimer et al.
CLINICAL CANCER RESEARCH (2017)
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas et al.
CELL (2017)
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy
Stefani Spranger et al.
CANCER CELL (2017)
Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors
Shannon M. Steinberg et al.
CANCER RESEARCH (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells
Alfonso R. Sanchez-Paulete et al.
CANCER DISCOVERY (2016)
Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition
Helene Salmon et al.
IMMUNITY (2016)
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
Olivier De Henau et al.
NATURE (2016)
Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells
Blanca Homet Moreno et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Endoplasmic Reticulum Stress in Immunity
Sarah E. Bettigole et al.
ANNUAL REVIEW OF IMMUNOLOGY VOL 33 (2015)
ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis
Juan R. Cubillos-Ruiz et al.
CELL (2015)
Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma
Lawrence N. Kwong et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Genetic Vaccines To Potentiate the Effective CD103+ Dendritic Cell-Mediated Cross-Priming of Antitumor Immunity
Yi Zhang et al.
JOURNAL OF IMMUNOLOGY (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Beatriz M. Carreno et al.
SCIENCE (2015)
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma
Siwen Hu-Lieskovan et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity
Miranda L. Broz et al.
CANCER CELL (2014)
Immune-Based Antitumor Effects of BRAF Inhibitors Rely on Signaling by CD40L and IFNγ
Ping-Chih Ho et al.
CANCER RESEARCH (2014)
TLR dependent XBP-1 activation induces an autocrine loop in rheumatoid arthritis synoviocytes
Sinisa Savic et al.
JOURNAL OF AUTOIMMUNITY (2014)
Combining Targeted Therapy With Immunotherapy in BRAF-Mutant Melanoma: Promise and Challenges
Siwen Hu-Lieskovan et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
The unfolded-protein-response sensor IRE-1α regulates the function of CD8α+ dendritic cells
Fabiola Osorio et al.
NATURE IMMUNOLOGY (2014)
BRAF Inhibition Alleviates Immune Suppression in Murine Autochthonous Melanoma
Shannon M. Steinberg et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Dendritic cell-derived interleukin-15 is crucial for therapeutic cancer vaccine potency
Yi Zhang et al.
ONCOIMMUNOLOGY (2014)
Mechanisms regulating skin immunity and inflammation
Manolis Pasparakis et al.
NATURE REVIEWS IMMUNOLOGY (2014)
BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
Chengwen Liu et al.
CLINICAL CANCER RESEARCH (2013)
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
Dennie T. Frederick et al.
CLINICAL CANCER RESEARCH (2013)
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Deborah A. Knight et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
The skin-resident and migratory immune system in steady state and memory: innate lymphocytes, dendritic cells and T cells
William R. Heath et al.
NATURE IMMUNOLOGY (2013)
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
James S. Wilmott et al.
CLINICAL CANCER RESEARCH (2012)
Genetic Targeting of the Active Transcription Factor XBP1s to Dendritic Cells Potentiates Vaccine-induced Prophylactic and Therapeutic Antitumor Immunity
Shenghe Tian et al.
MOLECULAR THERAPY (2012)
Resistance to BRAF Inhibitors: Unraveling Mechanisms and Future Treatment Options
Jessie Villanueva et al.
CANCER RESEARCH (2011)
ER stress and its regulator X-box-binding protein-1 enhance polyIC-induced innate immune response in dendritic cells
Fanlei Hu et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
Systems biology of vaccination for seasonal influenza in humans
Helder I. Nakaya et al.
NATURE IMMUNOLOGY (2011)
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Gideon Bollag et al.
NATURE (2010)
TLR activation of the transcription factor XBP1 regulates innate immune responses in macrophages
Fabio Martinon et al.
NATURE IMMUNOLOGY (2010)
BrafV600E cooperates with Pten loss to induce metastatic melanoma
David Dankort et al.
NATURE GENETICS (2009)
The transcription factor XBP-1 is essential for the development and survival of dendritic cells
Neal N. Iwakoshi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Cutting edge:: Re-evaluating the in vivo cytokine responses of CD8+ T cells during primary and secondary viral infections
F Liu et al.
JOURNAL OF IMMUNOLOGY (2005)
分享论文
